Exposure to oral bisphosphonates and risk of esophageal cancer

JAMA

Volumn 304, Issue 6, 2010, Pages 657-663

  Cardwell, Chris R ^a   Abnet, Christian C ^b   Cantwell, Marie M ^a   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER; UNITED KINGDOM;

EID: 77955369368     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1098     Document Type: Article

References (26)

1. Usher C, Teeling M, Bennett K, Feely J. Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol. 2006;62(4):307-310.
2. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 2006;21(5):765-771.
3. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol. 2007;63(9):843-849.
4. Ryan JM, Kelsey P, Ryan BM, Mueller PR. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture - radiographic features. Radiology. 1998;206(2):389-391.
5. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335(14):1016-1021.
6. Ribeiro A, DeVault KR, Wolfe JT III, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc. 1998;47(6): 525-528.
7. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274(6):474-477.
8. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340(11):825-831.
9. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma - a population-based cohort study. Am J Gastroenterol. 2006;101(6):1193-1199.
10. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(1):89-90.
11. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends. 1997; (87):36-40.
12. Kinn S, Lee N, Millman A. ABC of medical computing: using computers in clinical audit. BMJ. 1995; 311(7007):739-742.
13. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991; 302(6779):766-768.
14. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
15. The Anatomical Therapeutic Chemical Classification System With Defined Daily Doses. World Health Organization Web site. http://www.who.int/ classifications/atcddd/en/. Accessed July 15, 2010.
16. Office for National Statistics Web site. http://www.ons.gov.uk. Accessed July 15, 2010.
17. Breslow NE, Day NE. The Design and Analysis of Cohort Studies. Oxford, England: Oxford University Press; 1987.
18. Statistical Methods in Cancer Research; vol 2.
19. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98(3):665-672.
20. Giraudo E, Inoue M, Hanahan D. An aminobisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004;114(5):623-633.
21. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004;94(1): 164-170.
22. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 2008;34(suppl 1):S19-S24.
23. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med. 2009;360(17): 1789-1790.
24. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med. 2009;360(17):1791-1792.
25. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023-1031.
26. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349(9051):525-528.